Piet Ost, MD, PhD, is Professor at Ghent University in Belgium and Clinical Lead and Senior Clinical Investigator at Ghent University Hospital (UZ Gent). He qualified as a doctor at UZ Gent in 2006, received his PhD from Ghent University in 2011, and completed a specialization in radiotherapy at UZ Gent in 2012. He is also a senior clinical investigator in the Research Foundation – Flanders (FWO).
Together with his team, Professor Ost focuses on the multidisciplinary management of urothelial cancers, with a strong focus on prostate cancer. They have implemented new technologies such as intensity-modulated radiotherapy (IMRT), stereotactic body radiation therapy SBRT, and volumetric modulated arc therapy (VMAT) in urological tumours and have also used new systemic treatments such as abiraterone and enzalkutamide, as well as combining radiotherapy and immunotherapy in these cancers. Another important focus is the implementation of new diagnostic tools in the re-staging of prostate cancer and implementation of metastasis-directed therapy for oligometastatic prostate cancer and they are involved in developing prognostic or predictive biomarker panels, in collaboration with other departments within and beyond Ghent University.
Professor Ost has published widely in the field of urothelial oncology, with key publications in Lancet Oncology, Journal of Clinical Oncology, and European Urology.
Date of preparation: April 2020